USANA Health Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Equity-Based Compensation (Tables)

3 Months Ended

Mar. 29, 2014



2014		$ 6,784
2015		7,299
2016		5,420
2017		3,348
2018		541
		$ 23,392

The cost above is expected to be recognized over a weighted-average
period of 2.2 years.



	Three Months Ended
	March 30,	March 29,
	2013	2014

Expected volatility (1) .	43.7%	39.9%
Risk-free interest rate (2) .	0.6%	1.2%
Expected life (3) .	3.97 yrs	3.54 yrs
Expected dividend yield (4) .	0.0%	0.0%
Weighted-average exercise price (5) .	$ 38.69	$ 57.62

(1) The Company utilizes historical volatility of the trading price of its common stock.
(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of
the award.
(3) Depending upon the terms of the award, expected life may be a weighted-average that includes
historical settlement data of the Company's equity awards and a hypothetical holding
period for outstanding awards, or it may be calculated under the simplified method.
(4) The Company historically has not paid dividends.
(5) Exercise price is the closing price of the Company's common stock on the date of grant.


	Shares	Weighted-average exercise price	Weighted-average remaining contractual term	Aggregate intrinsic value*
Outstanding at December 28, 2013	1,827	$ 37.37	2.6	$ 74,160
Granted	669	57.62
Exercised	(160)	28.83
Forfeited	(20)	27.33
Expired	-	-

Outstanding at March 29, 2014	2,316	$ 43.90	3.0	$ 70,387

Exercisable at March 29, 2014	424	$ 37.96	1.9	$ 15,280

* Aggregate intrinsic value is defined as the difference between the current market value at the reporting date (the closing price of the
Company's common stock on the last trading day of the period) and the exercise price of awards that were in-the- money. The
closing price of the Company's common stock at December 28, 2013, and March 29, 2014, was $77.72 and $74.02, respectively.